Imbruvica®▾(ibrutinib) patient support programme for chronic lymphocytic leukaemia and mantle cell lymphoma.

about

Imbruvica®▾(ibrutinib) patient support programme for chronic lymphocytic leukaemia and mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q50982343

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Imbruvica®▾

@nl

Imbruvica®▾(ibrutinib) patient ...... emia and mantle cell lymphoma.

@en

type

Item

label

Imbruvica®▾

@nl

Imbruvica®▾(ibrutinib) patient ...... emia and mantle cell lymphoma.

@en

prefLabel

Imbruvica®▾

@nl

Imbruvica®▾(ibrutinib) patient ...... emia and mantle cell lymphoma.

@en

P1476

Imbruvica®▾(ibrutinib) patient ...... emia and mantle cell lymphoma.

@en

P2093

Shankara Paneesha

http://www.w3.org/2001/XMLSchema#string

Susan Weaving

http://www.w3.org/2001/XMLSchema#string

Vidhya Murthy

http://www.w3.org/2001/XMLSchema#string

P2860

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Cancer statistics, 2015

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

P304

S20-S25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12968/BJON.2017.26.10.S20

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28541116

http://www.w3.org/2001/XMLSchema#string

P921

leukemia